Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Arthur Strzepka

Emergency Medicine Albany, NY Medical Doctor

NPI 1821625625 CMS profile 11463588

47 New Scotland Ave, Albany, NY 12208

Open in the dashboard

General payments

$8,604

161 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arthur Strzepka of Albany, NY is reported in the CMS Open Payments database as having received $8,604 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,624 93
2024 General $3,555 56
2023 General $424 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arthur Strzepka
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Arthur Strzepka were reported at $4,624. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Arthur Strzepka Emergency Medicine median Middle half National median
2019 $0 $51 $18–$128 $163
2020 $0 $29 $16–$99 $114
2021 $0 $40 $18–$124 $132
2022 $0 $49 $20–$134 $149
2023 $424 $51 $22–$142 $160
2024 $3,555 $52 $22–$150 $164
2025 $4,624 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Boston Scientific Corporation $6,520 108 payments
  2. Saluda Medical Americas, Inc. $645 10 payments
  3. SI-BONE, Inc. $215 3 payments
  4. Nalu Medical, Inc. $184 1 payment
  5. AbbVie, Inc. $167 8 payments
  6. SPR Therapeutics, Inc $121 1 payment
  7. Vertex Pharmaceuticals Incorporated $110 5 payments
  8. Relievant Medsystems, Inc. $103 1 payment
  9. Spinal Simplicity, LLC $102 2 payments
  10. IBSA Pharma Inc. $70 5 payments
  11. Other $368 17 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,399 150 payments
  2. Travel and Lodging $3,205 11 payments
Products named General payments · program years 2023–2025
  1. Intracept $1,895 10 payments
  2. WaveWriter Alpha Prime 16 $1,638 50 payments
  3. General - Therapies $1,498 7 payments
  4. General - Pain Management $686 29 payments
  5. Evoke $645 10 payments
  6. Nalu Neurostimulation System $184 1 payment
  7. Intracept RF Probe $129 1 payment
  8. SPRINT PNS System $121 1 payment
  9. Infinion 16 $110 1 payment
  10. BOTOX $109 5 payments
  11. Other $1,298 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

81

Median for Emergency Medicine: 88

Drug cost

$854

Median for Emergency Medicine: $590

Branded share of claims

0%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 35 $462
Gabapentin Generic 28 $264
Methylprednisolone Generic 18 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$136,779

Of which drugs: $12,285

Medicare patients

457

Average age 73

Services billed

5,021

259 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 28%
Depression 25%
Chronic kidney disease 19%
Osteoporosis 19%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 22 57 $3,283
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 158 906 $678
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 18 32 $178
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 118 987 $103

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $26
$26 — —
NURTEC ODT
  • PFIZER INC. $23
$23 — —
ZAVZPRET
  • PFIZER INC. $23
$23 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $23
$23 — —
Tirosint
  • IBSA Pharma Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record